Editor's note

This article was originally published on 25 February 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The US approval pathway

The US Vaccines and Related Biological Products Advisory Committee (VRBPAC) had issued a positive recommendation for Rotarix in early 2008, bringing GSK Biologicals closer to US market entry in the rotavirus segment. Rotarix had already achieved approval and commercial launch in over 100 countries, with a strong European presence and GAVI-supported access in lower-income markets. The US approval, when granted, would represent the final significant regulatory milestone for the product.

Rotarix vs RotaTeq: the differentiation question

Both Rotarix (monovalent, human-derived, 2-dose) and RotaTeq (pentavalent, bovine-human reassortant, 3-dose) had demonstrated excellent efficacy and acceptable safety profiles. Clinical differentiation was subtle: Rotarix's simpler two-dose schedule was potentially advantageous for programme compliance, while RotaTeq's pentavalent approach offered broader serotype coverage in theory. In practice, both vaccines had demonstrated high real-world effectiveness against severe rotavirus gastroenteritis.

Rotarix Efficacy
>85%

Rotarix efficacy against severe rotavirus gastroenteritis in clinical trials, comparable to RotaTeq's clinical profile

"Rotarix's two-dose schedule and established international track record give GSK a credible differentiation story - but converting that story into US market share against an entrenched RotaTeq will require sustained commercial investment."